Yale AIDS Program, Section of Infectious Diseases, School of Medicine, School of Public Health, Yale University, New Haven, CT, USA.
Yale AIDS Program, Section of Infectious Diseases, School of Medicine, School of Public Health, Yale University, New Haven, CT, USA; Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, CT, USA; Centre of Excellence in Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia.
Lancet HIV. 2018 Nov;5(11):e617-e628. doi: 10.1016/S2352-3018(18)30175-9. Epub 2018 Sep 6.
People transitioning from prisons or jails have high mortality, but data are scarce for people with HIV and no studies have integrated data from both criminal justice and community settings. We aimed to assess all-cause mortality in people with HIV released from an integrated system of prisons and jails in Connecticut, USA.
We linked pharmacy, custodial, death, case management, and HIV surveillance data from Connecticut Departments of Correction and Public Health to create a retrospective cohort of all adults with HIV released from jails and prisons in Connecticut between 2007 and 2014. We compared the mortality rate of adults with HIV released from incarceration with the general US and Connecticut populations, and modelled time-to-death from any cause after prison release with Cox proportional hazard models.
We identified 1350 people with HIV who were released after 24 h or more of incarceration between 2007 and 2014, of whom 184 (14%) died after index release; median age was 45 years (IQR 39-50) and median follow-up was 5·2 years (IQR 3·0-6·7) after index release. The crude mortality rate for people with HIV released from incarceration was 2868 deaths per 100 000 person-years, and the standardised mortality ratio showed that mortality was higher for this cohort than the general US population (6·97, 95% CI 5·96-7·97) and population of Connecticut (8·47, 7·25-9·69). Primary cause of death was reported for 170 individuals; the most common causes were HIV/AIDS (78 [46%]), drug overdose (26 [15%]), liver disease (17 [10%]), cardiovascular disease (16 [9%]), and accidental injury or suicide (13 [8%]). Black race (adjusted hazard ratio [HR] 0·52, 95% CI 0·34-0·80), having health insurance (0·09, 0·05-0·17), being re-incarcerated at least once for 365 days or longer (0·41, 0·22-0·76), and having a high percentage of re-incarcerations in which antiretroviral therapy was prescribed (0·08, 0·03-0·21) were protective against mortality. Positive predictors of time-to-death were age (≥50 years; adjusted HR 3·65, 95% CI 1·21-11·08), lower CD4 count (200-499 cells per μL, 2·54, 1·50-4·31; <200 cells per μL, 3·44, 1·90-6·20), a high number of comorbidities (1·86, 95% CI 1·23-2·82), virological failure (2·76, 1·94-3·92), and unmonitored viral load (2·13, 1·09-4·18).
To reduce mortality after release from incarceration in people with HIV, resources are needed to identify and treat HIV, in addition to medical comorbidities, psychiatric disorders, and substance use disorders, during and following incarceration. Policies that reduce incarceration and support integrated systems of care between prisons and communities could have a substantial effect on the survival of people with HIV.
US National Institutes of Health.
从监狱或看守所获释的人死亡率较高,但针对没有感染艾滋病毒的人,相关数据却十分有限,而且也没有研究将刑事司法和社区环境的数据整合在一起。我们旨在评估从美国康涅狄格州监狱和看守所综合系统中释放的艾滋病毒感染者的全因死亡率。
我们将康涅狄格州惩教和公共卫生部门的药房、拘留、死亡、病例管理和艾滋病毒监测数据进行了关联,创建了一个从 2007 年至 2014 年期间从康涅狄格州监狱和看守所释放的所有成年艾滋病毒感染者的回顾性队列。我们比较了从监禁中释放的艾滋病毒感染者与美国和康涅狄格州普通人群的死亡率,并使用 Cox 比例风险模型对从监禁释放后的任何原因导致的死亡时间进行了建模。
我们确定了 1350 名在 2007 年至 2014 年期间至少被监禁 24 小时以上后获释的艾滋病毒感染者,其中 184 人(14%)在指数释放后死亡;中位年龄为 45 岁(IQR 39-50),中位随访时间为指数释放后 5.2 年(IQR 3.0-6.7)。从监禁中释放的艾滋病毒感染者的粗死亡率为每 100000 人年 2868 人,标准化死亡率比表明,该队列的死亡率高于美国普通人群(6.97,95%CI 5.96-7.97)和康涅狄格州人群(8.47,7.25-9.69)。报告了 170 名患者的主要死因;最常见的死因是艾滋病毒/艾滋病(78 [46%])、药物过量(26 [15%])、肝脏疾病(17 [10%])、心血管疾病(16 [9%])和意外损伤或自杀(13 [8%])。黑人种族(调整后的风险比[HR] 0.52,95%CI 0.34-0.80)、拥有健康保险(0.09,0.05-0.17)、至少被监禁 365 天或更长时间(0.41,0.22-0.76)、接受抗逆转录病毒治疗的监禁次数较高(0.08,0.03-0.21)与死亡率降低相关。与死亡时间相关的阳性预测因素包括年龄(≥50 岁;调整后的 HR 3.65,95%CI 1.21-11.08)、较低的 CD4 计数(200-499 个细胞/μL,2.54,1.50-4.31;<200 个细胞/μL,3.44,1.90-6.20)、较多的合并症(1.86,95%CI 1.23-2.82)、病毒学失败(2.76,1.94-3.92)和未监测的病毒载量(2.13,1.09-4.18)。
为了降低从监禁中释放的艾滋病毒感染者的死亡率,需要在监禁期间和监禁后识别和治疗艾滋病毒以及医疗合并症、精神障碍和物质使用障碍。减少监禁和支持监狱和社区之间综合护理系统的政策可能会对艾滋病毒感染者的生存产生重大影响。
美国国立卫生研究院。